Roger Perlmutter

Roger M.
Perlmutter is currently Chairman & Chief Executive Officer at Eikon Therapeutics, Inc. since 2021.
He is Chairman of The Reed Institute since 2012.
He serves as Independent Director at NGM Biopharmaceuticals, Inc. since 2021.
He is Director at the Institute for Systems Biology since 2013 and at Exonics Therapeutics, Inc. since 2018.
He is Independent Director at Insitro, Inc. since 2020.
He is a Science Partner at The Column Group LLC and a Member of the American Academy of Arts & Sciences.
Formerly, Dr. Perlmutter was Chairman-Immunology Department & Professor at the University of Washington from 1984 to 1997.
He was Independent Director at StemCells, Inc. from 2011 to 2013 and at Ablynx NV from 2012 to 2013.
He was President & Director at Alantos Pharmaceuticals Holding, Inc. He was Non-Executive Director at Merck Research Laboratories Massachusetts LLC in 2021.
He was Director at The Irvington Institute for Immunological Research from 1997 to 2001.
He was Non-Executive Director at Nxera Pharma UK Ltd. and Director at Immune Design Corp.
He was Executive Vice President & Head-Research & Development at Amgen, Inc. from 2001 to 2012.
He was Executive Vice President at Merck & Co., Inc. from 2013 to 2021 and EVP-Worldwide Basic & Preclinical Research at Merck & Co., Inc. from 1997 to 2001.
He was President of The American Association of Immunologists.
Education includes a doctorate from Washington University in St. Louis conferred in 1979 and an undergraduate degree from The Reed Institute conferred in 1973.